骨髓肿瘤微环境、HLA-I 和 HLA-Ib 表达对 MDS 和 CMML 发展为 sAML 的预后影响

IF 7.2 2区医学

Oncoimmunology Pub Date : 2024-03-06 DOI:10.1080/2162402x.2024.2323212

Marcus Bauer, Nadja Jäkel, Andreas Wilfer, Anja Haak, Markus Eszlinger, Katalin Kelemen, Monika Haemmerle, Haifa Kathrin Al-Ali, Barbara Seliger, Claudia Wickenhauser

引用次数: 0

摘要

基因畸变和免疫逃逸是 MDS 和 CMML 开始和发展为 sAML 的根本原因。因此，免疫细胞的定量和空间组织、免疫检测因子的表达、免疫细胞的...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Prognostic impact of the bone marrow tumor microenvironment, HLA-I and HLA-Ib expression in MDS and CMML progression to sAML

Genetic aberrations and immune escape are fundamental in MDS and CMML initiation and progression to sAML. Therefore, quantitative and spatial immune cell organization, expression of immune checkpoi...

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.